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• Breast cancer, with a 12.5% lifetime risk in general 
population, is the most frequent cancer in women. About 
5-10% of breast cancers are thought to be hereditary 
whereas the remaining 90%  is sporadic. 
 
• Most inherited cases of breast cancer are associated with 
two abnormal genes: BRCA1 (BReast CAncer gene one) and 
BRCA2 (BReast CAncer gene two) but these only make up 
25% of hereditary breast cancers while the remaining 75% 
is due to moderate and low penetrance and unknown 
genes.  
 
• Because of the lack of awareness of this pathology, it does 
not have a standard and harmless treatment to fight it so 
the research of novel therapies and the improvement of 
actual strategies would suppose a highly breakthrough in 
the disease. 
 
 
 
 
The aim of this divulgative work is to create an informative 
website intended for hereditary breast cancer patients and their 
relatives where the following objectives are reflected:   
• Explanation of what hereditary breast cancer is,           
focusing on BRCA genes.  
• Provide a description of BRCA mutation carriers’ features.  
• Provide the highlights of genetic counselling 
• Exposure the current available treatments             
• Show the novel therapies 
 
 
 
It was undertaken a critical review of journal articles published 
between 2001 and 2013, identified by searches in MEDLINE and 
PubMed using the following search terms: BRCA1, BRCA2, 
hereditary breast cancer, hereditary ovarian cancer, genetic 
counsellors, risk assessment, genetic susceptibility, medical 
outcomes and treatment. References of retrieved articles were 
undertaken. 
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Genetic causes: 
• 25% due to BRCA1/2 mutations  
• 5% is caused by other high susceptibility genes 
• 5% is composed by moderate susceptibility genes 
• 14% is formed by low susceptibility genes 
• 51% remains unknown  
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Conclusions 
Figure 4- Hypothesis for the tumor synthetic lethal strategy of 
Poly(ADP-Ribose) Polymerase (PARP) inhibitors in BRCA1/2 
mutation carriers (Yap TA et al., 2011) 
 
Breast cancer: 
•       Is the most common cancer in women with    
        230,000  women diagnosed in the US in 2012  
•       Its origin is: 
o 90% sporadic 
o 10-5% hereditary 
 
 
 
 
Genetic counselling is a useful procedure to: 
• Give the chance to perform a genetic testing 
• Assess patient about cancer risk  
• Give patients medical options to prevent cancer 
• The most useful and effective procedure to prevent 
breast/ovarian cancer is the prophylactic surgery of 
these organs 
 
Treatments  
Chemotherapy  Surgery 
Targeted 
therapies 
Table 1. Summary of known breast cancer predisposition genes 
(Adapted from Turnbull C and Rahman N,  2008) 
 
Penetrance 
 
Gene/Locus 
Carrier 
Frequency 
 
Cancers 
 
BRCA1 
 
0.1% 
 
Breast and ovarian  
High 
penetrance 
 
BRCA2 
 
0.1% 
 
Breast and ovarian  
 
TP53 Rare Sarcomas, adrenal and brain 
 
PTEN 
 
Rare 
 
Thyroid and endometrium 
Uncertain  
STK11 
 
Rare 
 
Gastrointestinal 
penetrance  
CDH1 
 
Rare 
 
Gastric 
 
ATM 
 
 
0.4% 
CHEK2 0.4% 
Intermediate BRIP1 0.1% 
penetrance PALB2 Rare 
RAD51 Rare  
Low 
penetrance 
10q26 
16q12q35, 
8q24, 5p12 
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Treatment: 
• Tumor-specific synthetic lethal strategy with 
PARP inhibitors is showing considerable 
potential for delivering selective tumor cell 
kill while sparing normal cells 
• Nowadays is being tested in clinical trials  
 
 
Figure 2- Genetic counseling algorithm (Berliner JL et al., 2007) 
 
One of the novel targeted therapies is tumor synthetic lethal 
strategy of Poly(ADP-Ribose) Polymerase (PARP) inhibitors 
Figure 1. The main high penetrance susceptibility genes: BRCA1 
and BRCA2 (Rohini Roy et al., 2012). 
Figure 3- Prophylactic surgery is 
the most effective procedure to 
prevent breast/ovarian cancer.  
Results from Rebbeck TR et al., 
2004 (A); Kauff ND et al., 2008 (B-
C) 
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